The discovery step includes three differential methylation analyses using (i) cancer GWAS-SS and meQTL-based genetic prediction models (i-MeWAS), (ii) tumour and healthy methylation samples (TH-DM) and (iii) tumour and histologically normal adjacent to the tumour (NAT) methylation samples (TN-DM). The gene discussed is BRD2; the disease is neoplasm.